“…In 2008, an rTMS device developed by Neuronetics was approved by the Food and Drug Administration in the United States for the treatment of patients with major depressive disorder who are resistant to at least one antidepressant drug (O'Reardon et al, 2007 ). rTMS has since been shown to have therapeutic potential for a range of psychiatric disorders, including unipolar (Xia et al, 2008 ; Gaynes et al, 2014 ) and bipolar depression (Xia et al, 2008 ), schizophrenia (Dlabac-de Lange et al, 2010 ), obsessive-compulsive disorder (Jaafari et al, 2012 ), and post-traumatic stress disorder (Clark et al, 2015 ) as well as in neurological conditions such as Parkinson's disease (Arias-Carrión, 2008 ), dystonia (Machado et al, 2011 ), tinnitus (Soleimani et al, 2015 ), epilepsy (Pereira et al, 2016 ), and stroke (Corti et al, 2012 ). rTMS has also shown promising results in the treatment of pain syndromes such as migraine (Lipton and Pearlman, 2010 ) and chronic pain (Galhardoni et al, 2015 ).…”